Загрузка...
Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors
PURPOSE: In 2009, the US Food and Drug Administration (FDA) mandated a label change for leukotriene inhibitors (LTIs) to include neuropsychiatric adverse events (eg, depression and suicidality) as a precaution. This study investigated how this label change affected the use of LTIs and other asthma c...
Сохранить в:
| Опубликовано в: : | Clin Ther |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5101625/ https://ncbi.nlm.nih.gov/pubmed/25920571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2015.03.027 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|